{"id":54902,"date":"2023-03-16T12:06:31","date_gmt":"2023-03-16T11:06:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/"},"modified":"2023-03-16T12:06:31","modified_gmt":"2023-03-16T11:06:31","slug":"lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/","title":{"rendered":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"},"content":{"rendered":"
\n

\nInstalled ten ALLY\u00ae<\/sup> Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023<\/i>\n<\/p>\n

\nPositive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY<\/i>\n<\/p>\n

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe reception to our next generation ALLY System supports our confidence in this new technology and its potential to change the cataract treatment landscape. With ten ALLY Systems installed at year end, surgeons using the system have been clear that ALLY has provided many significant and-desired improvements in surgical and operational efficiencies, resulting in economic benefits as compared to competing first generation devices. ALLY also reinforces the LENSAR value proposition by guiding excellent outcomes and improving the overall experience of the surgeon and their patients,\u201d said Nick Curtis, Chief Executive Officer of LENSAR.\n<\/p>\n

\nA. James Khodabakhsh, MD, Chief Department of Ophthalmology, Cedars-Sinai Medical Center, a pioneer in the field of premium cataract surgery and one of the first surgeons in the world to use femtosecond laser technology for cataract removal noted, \u201cMy surgery center is the only center in the country that owns three different femtosecond laser platforms, and the LENSAR ALLY System has cut an hour to an hour and a half off my day. ALLY is so fast and so accurate that I have added at least 3 to 4 cases onto my surgery days.”\n<\/p>\n

\nFourth Quarter 2022 Financial Results<\/b>\n<\/p>\n

\nTotal revenue for the quarter ended December 31, 2022 was $10.2 million, a decrease of $1.0 million, or 9%, compared to total revenue of $11.2 million for the quarter ended December 31, 2021. The decrease from the fourth quarter of 2021 was primarily due to a decrease in procedure revenue in South Korea.\n<\/p>\n

\nFor the quarters ended December 31, 2022 and 2021, approximately 73% and 80% of our revenue was attributable to recurring sources, respectively.\n<\/p>\n

\nSelling, general and administrative expenses for the quarter ended December 31, 2022 were $7.2 million, an increase of $1.4 million, or 24%, compared to $5.8 million for the quarter ended December 31, 2021. The increase was primarily due to increased professional fees of $0.7 million and sales and marketing expenses, which was primarily the result of increased trade show and commercial activity related to the promotion of the ALLY System.\n<\/p>\n

\nResearch and development expenses were $1.6 million and $3.4 million for the quarters ended December 30, 2022 and 2021, respectively, a decrease of $1.8 million or 53%. This decrease was primarily due to significantly lower costs for the development of the ALLY System in the fourth quarter of 2022, including approximately $1.1 million of inventory charged to R&D in the fourth quarter of 2021, which increased research and development expenses in that quarter. Following the U.S. commercial clearance of the ALLY System in June 2022, all ALLY System inventory costs were capitalized to inventory.\n<\/p>\n

\nNet loss for the quarter ended December 31, 2022, was $2.5 million, or ($0.24) per share, compared to net loss of $3.9 million, or ($0.41) per share, for the quarter ended December 31, 2021. Included within operating expenses are stock-based compensation expenses recorded for the quarters ended December 31, 2022 and 2021 of $1.7 million and $1.5 million, respectively.\n<\/p>\n

\nEarnings Before Interest, Taxes, Depreciation and Amortization (\u201cEBITDA\u201d) for the quarter ended December 31, 2022 was ($1.8) million, compared with ($3.1) million for the quarter ended December 31, 2021. Adjusted EBITDA, which we calculate by adding back stock-based compensation expense to EBITDA, was ($65,000) for the quarter ended December 31, 2022 and ($1.6) million for the quarter ended December 31, 2021. EBITDA and Adjusted EBITDA are non-GAAP financial measures, and a reconciliation of these measures to net loss is set forth below in this press release.\n<\/p>\n

\nFull Year 2022 Financial Results<\/b>\n<\/p>\n

\nTotal revenue for the year ended December 31, 2022 was $35.4 million, an increase of $0.9 million, or 3%, compared to total revenue of $34.5 million for the year ended December 31, 2021. The increase was primarily attributable to increased lease revenue during the year ended December 31, 2022. Fiscal 2022 was a transition year as the Company transitioned its manufacturing and sale of its first generation LENSAR Laser System to the ALLY System. LENSAR expects to return to 20%+ revenue growth in 2023 as it enters its first full launch year.\n<\/p>\n

\nFor the years ended December 31, 2022 and 2021, approximately 86% of our revenue was attributable to recurring sources. Our recurring revenue was consistent and composed a substantial portion of our total revenue for the years ended December 31, 2022 and 2021. The following table provides information about procedure volume:\n<\/p>\n\n\n\n\n\n\n\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n2020<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nQ1\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n38,901\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n28,122\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n23,225\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nQ2\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n33,359\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n30,966\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n18,265\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nQ3\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n28,453\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n30,765\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n25,078\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nQ4\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n31,400\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n41,642\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n30,503\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n132,113\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n131,495\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n97,071\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nSelling, general, and administrative expenses for the year ended December 31, 2022 were $27.2 million, an increase of $3.3 million, or 14%, compared to $23.9 million for the year ended December 31, 2021. The increase was due to increases in sales and marketing expenses of $1.3 million, which was primarily the result of increased trade show and commercial activity related to the promotion of the ALLY System, and professional fees of $1.5 million. We expect selling, general and administrative expenses to continue to increase from current levels to support the commercialization of the ALLY System.\n<\/p>\n

\nResearch and development expenses were $11.8 million for the year ended December 31, 2022, a decrease of $0.5 million, or 4%, compared with $12.4 million for the year ended December 31, 2021. Research and development expenses in the year ended December 31, 2022 decreased from 2021 associated with the 510 (k) submission to the Food and Drug Administration (\u201cFDA\u201d) and subsequent U.S. FDA clearance of ALLY in June 2022. Inventory costs for the manufacture of ALLY Systems of $3.4 million and $3.7 million were included in R&D expense for the years ended December 31, 2022 and 2021, respectively.\n<\/p>\n

\nFollowing the U.S. commercial clearance of ALLY System in June 2022, we expect research and development expenses to decrease in the future.\n<\/p>\n

\nNet loss for the year ended December 31, 2022 was $19.9 million, or ($1.96) per share, as compared to a net loss of $19.6 million, or ($2.09) per share, for the year ended December 31, 2021. Total stock-based compensation expense recorded for the year ended December 31, 2022 and 2021 was $6.6 million and $6.9 million, respectively.\n<\/p>\n

\nEBITDA for the year ended December 31, 2022 was ($16.8) million, compared with ($16.9) million for the year ended December 31, 2021. Adjusted EBITDA was ($10.2) million for the year ended December 31, 2022, compared with ($10.0) million for the year ended December 31, 2021.\n<\/p>\n

\nAs of December 31, 2022, the Company had cash and cash equivalents of $14.7 million as compared to $31.6 million at December 31, 2021. Cash utilized in the quarter ended December 31, 2022 was $4.6 million and $17.0 million for full year 2022.\n<\/p>\n

\nConference Call:<\/b>\n<\/p>\n

\nLENSAR management will host a conference call and live webcast to discuss the fourth quarter and fiscal year results and provide a business update today, March 16, 2023 at 8:30 a.m. ET.\n<\/p>\n

\nTo participate by telephone, please dial (888) 886-7786 (Domestic) or (416) 764-8658 (International). The conference ID number is 94867603. The live webcast can be accessed under \u201cEvents & Presentations” in the Investor Relations section of the company’s website at https:\/\/ir.lensar.com<\/a>. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The call and webcast replay will be available until March 31, 2023.\n<\/p>\n

\nAbout LENSAR<\/b>\n<\/p>\n

\nLENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of visually significant astigmatism as an integral aspect of the cataract procedure. LENSAR has developed its next-generation ALLY\u00ae<\/sup> Adaptive Cataract Treatment System, the first platform to integrate proprietary imaging and software, with an extremely fast dual-pulse femtosecond laser in a compact, highly ergonomic system. ALLY is designed to transform cataract surgery by utilizing LENSAR\u2019s advanced technologies with the ability to perform the entire procedure in an operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR\u2019s proprietary Streamline\u00ae<\/sup> software technology, designed to guide surgeons to achieve better outcomes.\n<\/p>\n

\nForward-looking Statements<\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company\u2019s business strategies, commercialization and production of the ALLY\u00ae<\/sup> Adaptive Cataract Treatment System, and the ALLY System\u2019s performance and market impact. In some cases, you can identify forward-looking statements by terms such as \u201caim,\u201d \u201canticipate,\u201d \u201capproach,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook,\u201d \u201cmay,\u201d \u201cmission,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpursue,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof and similar words and expressions.\n<\/p>\n

\nForward-looking statements are based on management\u2019s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: the Company\u2019s history of operating losses and ability to generate revenue; its ability to maintain, grow market acceptance of and enhance its LENSAR Laser and ALLY Systems; the impact of the COVID-19 pandemic and the Company\u2019s ability to grow revenues; the Company\u2019s ability to obtain any additional necessary clearances or approvals for the ALLY System; the willingness of patients to pay the price difference for LENSAR products; its ability to grow a U.S. sales and marketing organization; its ability to meet its future capital needs; the impact of any material disruption to the supply or manufacture of ALLY Systems and its recurring revenue products; the ability of the Company to compete against competitors that have longer operating histories and more established products than the Company; the Company\u2019s ability to address numerous international business risks; and the other important factors that are disclosed under the heading \u201cRisk Factors\u201d contained in the Company\u2019s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the Securities and Exchange Commission (\u201cSEC\u201d), as such factors may be updated from time to time in its other filings with the SEC, including the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, to be filed with the SEC, each accessible on the SEC\u2019s website at www.sec.gov<\/a> and the Investor Relations section of the Company\u2019s website at https:\/\/ir.lensar.com<\/a>.\n<\/p>\n

\nAll forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing LENSAR\u2019s views as of any date subsequent to the date of this press release.\n<\/p>\n

\nNon-GAAP Financial Measures<\/b>\n<\/p>\n

\nThe Company prepares and analyzes operating and financial data and non-GAAP measures to assess the performance of its business, make strategic and offering decisions and build its financial projections. The key non-GAAP measures it uses are EBITDA and Adjusted EBITDA.\n<\/p>\n

\nEBITDA is defined as net loss before interest expense, interest income, income tax expense, depreciation and amortization expenses. EBITDA is a non-GAAP financial measure. EBITDA is specifically disclosed because the Company believes that EBITDA provides meaningful supplemental information for investors regarding the performance of its business and facilitates a meaningful evaluation of actual results on a comparable basis with historical results. Adjusted EBITDA is also a non-GAAP financial measure. The Company believes Adjusted EBITDA, which excludes stock-based compensation expense, provides meaningful supplemental information for investors when evaluating its results and comparing it to peer companies as stock-based compensation expense is a significant non-cash charge due to the recapitalization of the Company. It uses these non-GAAP financial measures in order to have comparable financial results to analyze changes in its underlying business from quarter to quarter. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance and, therefore, any non-GAAP measures it use may not be directly comparable to similarly titled measures of other companies.\n<\/p>\n

\nA reconciliation of EBITDA and Adjusted EBITDA to their most comparable GAAP financial measure are set forth below.\n<\/p>\n\n\n\n\n\n\n\n\n\n\n
<\/td>\n\n

\nThree Months Ended December 31,<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\nYear Ended December 31,<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n(Dollars in thousands)<\/b>\n<\/p>\n<\/td>\n

\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet loss\n<\/p>\n<\/td>\n

\n

\n$\n<\/p>\n<\/td>\n

\n

\n(2,490\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(3,902\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(19,914\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(19,601\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLess: Interest income\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(123\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(10\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(263\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(51\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdd: Depreciation expense\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n577\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n461\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,258\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,524\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdd: Amortization expense\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n276\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n309\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,148\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,240\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEBITDA\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(1,760\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(3,142\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(16,771\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(16,888\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdd: Stock-based compensation expense\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,695\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,543\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,611\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,866\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdjusted EBITDA\n<\/p>\n<\/td>\n

\n

\n$\n<\/p>\n<\/td>\n

\n

\n(65\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(1,599\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(10,160\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(10,022\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nLENSAR, Inc.<\/b>\n<\/p>\n

\nSTATEMENTS OF OPERATIONS<\/b>\n<\/p>\n

\n(In thousands, except per share amounts)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n\n

\nThree Months Ended December 31,<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\nYear Ended December 31,<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nRevenue<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nProduct\n<\/p>\n<\/td>\n

\n

\n$\n<\/p>\n<\/td>\n

\n

\n7,771\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n8,948\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n25,959\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n26,246\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLease\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,629\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,430\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n5,915\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,966\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nService\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n832\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n844\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,484\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,247\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal revenue\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,232\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,222\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n35,358\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n34,459\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCost of revenue (exclusive of amortization)<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nProduct\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,262\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,474\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n8,910\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,845\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLease\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n495\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n408\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,941\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,375\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nService\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n993\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n710\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,552\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,406\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal cost of revenue\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,750\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n5,592\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n15,403\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n16,626\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nSelling, general and administrative expenses\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n7,204\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n5,811\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n27,170\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n23,887\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nResearch and development expenses\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,615\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,422\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,814\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n12,358\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAmortization of intangible assets\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n276\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n309\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,148\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,240\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating loss<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(2,613\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(3,912\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(20,177\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(19,652\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther income<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nOther income, net\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n123\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n263\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n51\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet loss<\/b>\n<\/p>\n<\/td>\n

\n

\n$\n<\/p>\n<\/td>\n

\n

\n(2,490\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(3,902\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(19,914\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(19,601\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet loss per share<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nBasic and diluted\n<\/p>\n<\/td>\n

\n

\n$\n<\/p>\n<\/td>\n

\n

\n(0.24\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(0.41\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(1.96\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(2.09\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWeighted-average number of shares used in calculation of net loss per share:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nBasic and diluted\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,364\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n9,559\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,159\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n9,374\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nLENSAR, Inc.<\/b>\n<\/p>\n

\nBALANCE SHEETS<\/b>\n<\/p>\n

\n(In thousands, except per share amounts)<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n\n

\nAs of December 31,<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAssets<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCurrent assets:\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCash and cash equivalents\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n14,674\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n31,637\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAccounts receivable, net of allowance of $56 and $47, respectively\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,040\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,638\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNotes receivable, net of allowance of $4 and $61, respectively\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n200\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n350\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInventories\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,740\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,488\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPrepaid and other current assets\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,062\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n1,700\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal current assets\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n33,716\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n44,813\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nProperty and equipment, net\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n563\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n756\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nEquipment under lease, net\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,316\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n6,690\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNotes and other receivables, long-term, net of allowance of $9 and $2, respectively\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n442\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n121\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nIntangible assets, net\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n12,122\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n10,870\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther assets\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,685\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n3,215\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal assets<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n55,844\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n66,465\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLiabilities and stockholders\u2019 equity<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nCurrent liabilities:\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nAccounts payable\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n5,422\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n2,694\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAccrued liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,700\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n4,604\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDeferred revenue\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n768\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n904\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating lease liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n531\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n512\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal current liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,421\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n8,714\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLong-term operating lease liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,272\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2,803\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther long-term liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n167\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n69\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal liabilities\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n13,860\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n11,586\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nStockholders\u2019 equity:\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
\n

\nPreferred stock, par value $0.01 per share, 10,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u2014\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n\u2014\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCommon stock, par value $0.01 per share, 150,000 shares authorized at December 31, 2022 and 2021; 11,093 and 10,990 shares issued and outstanding at December 31, 2022 and 2021, respectively\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n111\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n110\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAdditional paid-in capital\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n139,381\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n132,363\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAccumulated deficit\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(97,508\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n(77,594\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal stockholders\u2019 equity\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n41,984\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n54,879\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal liabilities and stockholders\u2019 equity<\/b>\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n55,844\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n66,465\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n\u00a0\n<\/p>\n

Contacts<\/b> <\/p>\n

\nThomas R. Staab, II, CFO
\n
ir.contact@lensar.com<\/a><\/p>\n

Lee Roth \/ Cameron Radinovic
\n
Burns McClellan for LENSAR
\n
lroth@burnsmc.com<\/a> \/ cradinovic@burnsmc.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Installed ten ALLY\u00ae Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54902","6":"format-standard","7":"category-industry"},"yoast_head":"\nLENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Installed ten ALLY\u00ae Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T11:06:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update\",\"datePublished\":\"2023-03-16T11:06:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/\"},\"wordCount\":2286,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005818\\\/en\\\/1739781\\\/21\\\/LNSR_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/\",\"name\":\"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005818\\\/en\\\/1739781\\\/21\\\/LNSR_Logo.jpg\",\"datePublished\":\"2023-03-16T11:06:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005818\\\/en\\\/1739781\\\/21\\\/LNSR_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230315005818\\\/en\\\/1739781\\\/21\\\/LNSR_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/","og_locale":"en_US","og_type":"article","og_title":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend","og_description":"Installed ten ALLY\u00ae Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 2022; Installations expected in first half 2023 Positive surgeon feedback reinforces next generation speed, efficiency and economic benefits of ALLY ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (\u201cLENSAR\u201d or \u201cthe Company\u201d), a global medical technology company focused ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-16T11:06:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update","datePublished":"2023-03-16T11:06:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/"},"wordCount":2286,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/","url":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/","name":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg","datePublished":"2023-03-16T11:06:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230315005818\/en\/1739781\/21\/LNSR_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/lensar-reports-fourth-quarter-and-full-year-2022-results-and-provides-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54902"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54902\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}